Neuro drugs dumped by AbbVie are now heading to Neurocrine for $100M up front

Healthcare

brain x-ray image

AbbVie returned the rights to the drugs to Sosei Heptares earlier this year. Now Neurocrine Biosciences has agreed to pay the Japanese drug company $100 million to license the rights to these preclinical and clinical-stage compounds that address muscarinic receptors to potentially treat a range of neurological disorders.

Leave a Reply